{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:59:34Z","timestamp":1780919974122,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-026-02952-0","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:03:57Z","timestamp":1780916637000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Conformity with guideline-directed medical therapy and clinical outcomes in secondary cardiovascular prevention\u2014results of a German claims data analysis"],"prefix":"10.1007","author":[{"given":"Sven","family":"Wassmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Weisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1099-0856","authenticated-orcid":false,"given":"Olaf","family":"Randerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Predel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2952_CR1","unstructured":"European Society of Cardiology. EU 27 Cardiovascular Realities 2025.\u00a0https:\/\/www.flipsnack.com\/escardio\/eu-27-cardiovascular-realities-2025\/full-view.html\u00a004. Aug 2025"},{"key":"2952_CR2","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1161\/CIRCULATIONAHA.115.018931","volume":"133","author":"A Hartley","year":"2016","unstructured":"Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J (2016) Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe. Circulation 133:1916\u20131926","journal-title":"Circulation"},{"key":"2952_CR3","doi-asserted-by":"publisher","first-page":"E954","DOI":"10.1503\/cmaj.161142","volume":"189","author":"JD Edwards","year":"2017","unstructured":"Edwards JD, Kapral MK, Fang J, Swartz RH (2017) Long-term morbidity and mortality in patients without early complications after stroke or transient ischemic attack. CMAJ 189:E954-e961","journal-title":"CMAJ"},{"key":"2952_CR4","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","volume":"42","author":"KMWC Mohan","year":"2011","unstructured":"Mohan KMWC, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP (2011) Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 42:1489\u20131494","journal-title":"Stroke"},{"key":"2952_CR5","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1161\/01.STR.0000190118.02275.33","volume":"36","author":"EVO Touz\u00e9","year":"2005","unstructured":"Touz\u00e9 EVO, Chatellier G, Peyrard S, Rothwell PM, Mas JL (2005) Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke 36:2748\u20132755","journal-title":"Stroke"},{"issue":"3","key":"2952_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/clc.23160","volume":"42","author":"S Li","year":"2019","unstructured":"Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, Guo H et al (2019) Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol 42(3):391\u2013399","journal-title":"Clin Cardiol"},{"key":"2952_CR7","volume":"8","author":"SP Karunathilake","year":"2018","unstructured":"Karunathilake SP, Ganegoda GU (2018) Secondary prevention of cardiovascular diseases and application of technology for early diagnosis. Biomed Res Int 8:5767864","journal-title":"Biomed Res Int"},{"key":"2952_CR8","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37:2315\u20132381","journal-title":"Eur Heart J"},{"key":"2952_CR9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42:3227\u20133337","journal-title":"Eur Heart J"},{"issue":"7","key":"2952_CR10","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D et al (2021) 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke 52(7):e483\u2013e484","journal-title":"Stroke"},{"key":"2952_CR11","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","volume":"7","author":"J Dawson","year":"2022","unstructured":"Dawson J, B\u00e9jot Y, Christensen LM, De Marchis GM, Dichgans M, Hagberg G et al (2022) European stroke organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J 7:I\u2013XLI","journal-title":"Eur Stroke J"},{"key":"2952_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s42451-022-00461-8","volume":"5","author":"GF Hamann","year":"2022","unstructured":"Hamann GF, Sander D, Grau A, R\u00f6ther J (2022) S2k-Leitlinie: Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke (TIA)\u00a0\u2013 Teil\u00a01 und Teil\u00a02. DGNeurologie 5:369\u2013380","journal-title":"DGNeurologie"},{"key":"2952_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2020","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL et al (2020) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42:1289\u20131367","journal-title":"Eur Heart J"},{"key":"2952_CR14","doi-asserted-by":"crossref","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano et al (2019) ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41:407\u2013477","DOI":"10.1093\/eurheartj\/ehz901"},{"key":"2952_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1185\/03007995.2011.590969","volume":"27","author":"U Zeymer","year":"2011","unstructured":"Zeymer U, J\u00fcnger C, Zahn R, Bauer T, Bestehorn K, Senges J (2011) Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr Med Res Opin 27:1563\u20131570","journal-title":"Curr Med Res Opin"},{"key":"2952_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-01866-1","volume":"21","author":"E Pedersen","year":"2021","unstructured":"Pedersen E, Garcia BH, Halvorsen KH, Eggen AE, Schirmer H, Waaseth M (2021) Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Troms\u00f8 7. BMC Cardiovasc Disord 21:44. https:\/\/doi.org\/10.1186\/s12872-021-01866-1","journal-title":"BMC Cardiovasc Disord"},{"key":"2952_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02321-x","author":"P L\u00f5iveke","year":"2021","unstructured":"L\u00f5iveke P, Marandi T, Ainla T, Fischer K, Eha J (2021) Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018. BMC Cardiovasc Disord. https:\/\/doi.org\/10.1186\/s12872-021-02321-x","journal-title":"BMC Cardiovasc Disord"},{"key":"2952_CR18","doi-asserted-by":"crossref","unstructured":"Solomon MD, Leong TK, Levin E, MD, Rana JS, Jaffe MG, Sidney S et al (2020) Cumulative adherence to secondary prevention guidelines and mortality after acute myocardial infarction.\u00a0J Am Heart Assoc 9(6):e014415","DOI":"10.1161\/JAHA.119.014415"},{"issue":"2","key":"2952_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-042878","volume":"11","author":"S Soldati","year":"2021","unstructured":"Soldati S, Di Martino M, Castagno D, Davoli M, Fusco D (2021) In-hospital myocardial infarction and adherence to evidence-based drug therapies: a real-world evaluation. BMJ Open 11(2):e042878","journal-title":"BMJ Open"},{"issue":"19","key":"2952_CR20","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.3390\/jcm10194472","volume":"10","author":"BL Roszak","year":"2021","unstructured":"Roszak BL, Banach M, Skrzypek M, Windak A, Tomasik T, Mastej M et al (2021) Secondary stroke prevention in Polish adults: results from the LIPIDOGRAM2015 Study. J Clin Med 10(19):4472","journal-title":"J Clin Med"},{"issue":"11","key":"2952_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064277","volume":"12","author":"M Wolf","year":"2022","unstructured":"Wolf M, Hasselstr\u00f6m JK, Carlsson A, von Euler M, Hasselstr\u00f6m J (2022) Identifying factors explaining practice variation in secondary stroke prevention in primary care: a cohort study based on all patients with ischaemic stroke in the Stockholm region. BMJ Open 12(11):e064277","journal-title":"BMJ Open"},{"key":"2952_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13579","volume":"9","author":"E O\u2019Brien","year":"2023","unstructured":"O\u2019Brien E, Milentijevic D, Roychowdhury R, Mitra S, Chen CY (2023) Antiplatelet treatment patterns and outcomes of secondary stroke prevention in the United States. Heliyon 9:e13579","journal-title":"Heliyon"},{"issue":"S01","key":"2952_CR23","volume":"78","author":"E Swart","year":"2016","unstructured":"Swart E, Bitzer EM, Gothe H, Harling M, Hoffmann F, Horenkamp-Sonntag D et al (2016) STandardisierte BerichtsROutine f\u00fcr Sekund\u00e4rdaten Analysen (STROSA) \u2013 ein konsentierter Berichtsstandard f\u00fcr Deutschland, Version 2. Gesundheitswesen 78(S01):e161","journal-title":"Gesundheitswesen"},{"issue":"10","key":"2952_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1055\/s-0029-1239517","volume":"71","author":"G Glaeske","year":"2009","unstructured":"Glaeske G, Augustin M, Abholz H, Banik N, Br\u00fcggenj\u00fcrgen B, Hasford J et al (2009) Epidemiologische Methoden f\u00fcr die Versorgungsforschung. Gesundheitswesen 71(10):685\u2013693","journal-title":"Das Gesundheitswesen"},{"issue":"1","key":"2952_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee, International Society of Pharmacoepidemiology","year":"2016","unstructured":"Public Policy Committee, International Society of Pharmacoepidemiology (2016) Guidelines for good pharmacoepidemiology practice (GPP),\u201d. Pharmacoepidemiol Drug Saf 25(1):2\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2952_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.2229","volume":"21","author":"GC Hall","year":"2012","unstructured":"Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, Lo Casale R (2012) Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 21(1):1\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2952_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG et al (2015) Gute Praxis Sekund\u00e4rdatenanalyse (GPS): Leitlinien und Empfehlungen. Das Gesundheitswesen 77(2):120\u2013126","journal-title":"Das Gesundheitswesen"},{"issue":"1","key":"2952_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1573403X12666160504100025","volume":"13","author":"J Engel","year":"2017","unstructured":"Engel J, Damen NL, van der Wulp I, de Bruijne MC, Wagner C (2017) Adherence to cardiac practice guidelines in the management of Non-ST-elevation acute coronary syndromes: a systematic literature review. Curr Cardiol Rev 13(1):3\u201327","journal-title":"Curr Cardiol Rev"},{"issue":"17","key":"2952_CR29","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/eurheartj\/ehx478","volume":"39","author":"P Widimsky","year":"2018","unstructured":"Widimsky P, Doehner W, Diener HC, Van Gelder IC, Halliday A, Mazighi M, ESC Council on Stroke (2018) The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. Eur Heart J 39(17):1567\u20131573","journal-title":"Eur Heart J"},{"key":"2952_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","volume":"387","author":"JM Castellano","year":"2022","unstructured":"Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A et al (2022) Polypill strategy in secondary cardiovascular prevention. N Engl J Med 387:967\u2013977","journal-title":"N Engl J Med"},{"issue":"4","key":"2952_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ANS.0000000000000263","volume":"42","author":"M Beauchemin","year":"2019","unstructured":"Beauchemin M, Cohn E, Shelton RC (2019) Implementation of clinical practice guidelines in the health care setting: a concept analysis. ANS Adv Nurs Sci 42(4):307\u2013324","journal-title":"ANS Adv Nurs Sci"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02952-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02952-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02952-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:04:03Z","timestamp":1780916643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02952-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":31,"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02952-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TW did studies for various pharmaceutical companies and received grants from Cytel Inc., a consultancy working for these companies.\u00a0SW is on the speaker and advisory bureau of Amgen, Apontis, AstraZeneca, Berlin Chemie, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Novartis, and Pfizer.\u00a0OR is a member of the Medical Department of APONTIS PHARMA Deutschland GmbH & Co. KG, Germany.\u00a0The remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}